OTCMKTS:ZLDPF Zealand Pharma A/S (ZLDPF) Stock Price, News & Analysis $65.16 +1.80 (+2.84%) As of 04/25/2025 12:35 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort InterestBuy This Stock About Zealand Pharma A/S Stock (OTCMKTS:ZLDPF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Zealand Pharma A/S alerts:Sign Up Key Stats Today's Range$63.30▼$65.1650-Day Range$58.87▼$108.3052-Week Range$57.97▼$141.74Volume758 shsAverage Volume950 shsMarket Capitalization$4.63 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingStrong Buy Company OverviewZealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.Read More… Receive ZLDPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address ZLDPF Stock News HeadlinesZealand Pharma begins mid-stage trial for obesity drug candidate in people with type 2 diabetesApril 24, 2025 | reuters.comZealand Pharma appoints Utpal Singh as CSOApril 23, 2025 | markets.businessinsider.comTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.April 29, 2025 | American Alternative (Ad)Zealand Pharma Hires Lilly Executive as Biotech Ramps Up in ObesityApril 23, 2025 | msn.comZealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025April 19, 2025 | finance.yahoo.comZealand Pharma Goes on Hiring Spree as It Gears Up for Obesity Tie-Up With RocheApril 11, 2025 | wsj.comGubra’s obesity drug trial success weighs on Zealand Pharma stockApril 2, 2025 | investing.comZealand Pharma upgraded to Overweight from Equal Weight at Morgan StanleyMarch 21, 2025 | markets.businessinsider.comSee More Headlines ZLDPF Stock Analysis - Frequently Asked Questions How have ZLDPF shares performed this year? Zealand Pharma A/S's stock was trading at $102.36 on January 1st, 2025. Since then, ZLDPF stock has decreased by 36.3% and is now trading at $65.16. View the best growth stocks for 2025 here. How were Zealand Pharma A/S's earnings last quarter? Zealand Pharma A/S (OTCMKTS:ZLDPF) announced its quarterly earnings results on Thursday, February, 20th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.19. The company had revenue of $1.30 million for the quarter, compared to analyst estimates of $28.11 million. Zealand Pharma A/S had a negative net margin of 1,725.03% and a negative trailing twelve-month return on equity of 15.24%. How do I buy shares of Zealand Pharma A/S? Shares of ZLDPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings2/20/2025Today4/29/2025Next Earnings (Estimated)5/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:ZLDPF Previous SymbolNASDAQ:ZLDPF CIKN/A Webwww.zealandpharma.com Phone45-8877-3600Fax45-8877-3898Employees340Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-102,180,000.00 Net Margins-1,725.03% Pretax Margin-1,383.25% Return on Equity-15.24% Return on Assets-13.77% Debt Debt-to-Equity Ratio0.03 Current Ratio35.49 Quick Ratio35.49 Sales & Book Value Annual Sales$9.09 million Price / Sales509.12 Cash FlowN/A Price / Cash FlowN/A Book Value$4.49 per share Price / Book14.51Miscellaneous Outstanding Shares71,024,000Free FloatN/AMarket Cap$4.63 billion OptionableNot Optionable Beta0.81 Social Links A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (OTCMKTS:ZLDPF) was last updated on 4/29/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zealand Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Zealand Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.